Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 19/20 | 0.63 |
| ▸ | F11 | P03951 | 3/20 | 0.47 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217656 | 1.00 | CFD (0.63) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL23217673 | 0.92 | CFD (0.66) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL30009834 | 0.92 | CFD (0.66) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL29672950 | 0.91 | CFD (0.65) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL23217455 | 0.91 | CFD (0.65) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL23217641 | 0.91 | CFD (0.55) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL30009856 | 0.91 | CFD (0.55) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL21438756 | 0.90 | CFD (0.67) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL23217462 | 0.89 | CFD (0.62) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL30010389 | 0.89 | CFD (0.62) | CFDF11TPSB2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |